Navigation Links
Corrected: XTL Biopharmaceuticals to Convene Extraordinary Shareholders' Meetings after Receipt of Shareholder Letter
Date:2/5/2009

VALLEY COTTAGE, N.Y., Feb. 5 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE: XTL) today provided notification that on February 3, 2009 the Company received a letter from a shareholder who owns more than 5% of the Company's outstanding ordinary shares requesting the convening of an extraordinary shareholders' meeting (EGM) of the Company as soon as possible to address and approve the following matters:

1. that Boaz Shweiger be and is hereby appointed as a Director of the Company until the next annual general meeting of the Company;

2. that Mark Allouche be and is hereby appointed as a Director of the Company until the next annual general meeting of the Company;

3. that Amit Yonay be and is hereby appointed as a Director of the Company until the next annual general meeting of the Company;

4. that David Grossman be and is hereby appointed as a Director of the Company until the next annual general meeting of the Company;

5. that Yaron Diament be and is hereby appointed as an External Director of the Company until March 11, 2012;

6. that Dafna Cohen be and is hereby appointed as an External Director of the Company until March 11, 2012;

7. that the share capital of the Company be consolidated and re-divided so that each five (5) shares of NIS 0.02 nominal value shall be consolidated into one (1) share of NIS 0.1 nominal value;

8. that the registered share capital of the Company be increased from NIS 10,000,000 divided into 100,000,000 ordinary shares, NIS 0.1 nominal value, to NIS 70,000,000 divided into 700,000,000 ordinary shares, NIS 0.1 nominal value;

9. that the ADR ratio be amended from one (1) ADR representing two (2) ordinary shares, NIS 0.1 nominal value, to one (1) ADR representing twenty (20) ordinary shares, NIS 0.1 nominal value;

10. and that the remuneration terms for Boaz Shweiger, Mark Allouche, Amit Yonay, David Grossman, Yaron Diament and Dafna Cohen, as set forth in the Notice is hereby approved.

Upon the approval of the appointment of the aforesaid Directors, all of the Company's current Directors shall immediately tender their resignation.

The EGMs will take place at the Conference Room at the Company's Israeli offices at Building 3, Kiryat Weizmann Science Park, Rehovot, Israel 76100, at 3:00 p.m. and 5:30 p.m. Israel time on March 11, 2009.


'/>"/>
SOURCE XTL Biopharmaceuticals Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
2. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
3. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
4. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
5. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
6. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
7. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
8. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
9. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
10. Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors
11. XTL Biopharmaceuticals Ltd. AGM / EGM Postponed Until October 2, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... ... The AMA is happy to announce that $48,000 in scholarships will be awarded ... created through funds donated by model aviation organizations and individuals, AMA members, and a ... Committee, which is made up of model aviation pilots and enthusiasts. The committee evaluates ...
(Date:4/20/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... prevention of migraine at the American Academy of Neurology ... 2017, in Boston . ... safety and patient outcomes data for galcanezumab in patients ... monthly migraine headache days among patients with episodic migraine. ...
(Date:4/20/2017)... ... April 20, 2017 , ... Energetiq Technology , ... today that Chief Executive Officer (CEO) Debbie Gustafson has been appointed to the ... industry association connecting the electronics manufacturing supply chain. The mission of the SEMI ...
(Date:4/20/2017)... For today, Stock-Callers.com redirects investors, attention to Biotechnology, ... research aimed at treating diseases and medical conditions. Under evaluation ... (NASDAQ: KERX), Kite Pharma Inc. (NASDAQ: KITE), and ZIOPHARM Oncology ... complimentary research reports on these stocks now at: ... http://stock-callers.com/registration Biostage ...
Breaking Biology Technology:
(Date:4/17/2017)... 2017 NXT-ID, Inc. (NASDAQ: NXTD ) ... of its 2016 Annual Report on Form 10-K on Thursday April ... ... in the Investor Relations section of the Company,s website at ... at http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/13/2017)... 13, 2017 According to a new market research ... Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and ... is expected to grow from USD 14.30 Billion in 2017 to USD ... 17.3%. ... MarketsandMarkets Logo ...
(Date:4/11/2017)... Research and Markets has announced the addition ... their offering. ... tracking market to grow at a CAGR of 30.37% during the ... 2017-2021, has been prepared based on an in-depth market analysis with ... its growth prospects over the coming years. The report also includes ...
Breaking Biology News(10 mins):